Current/ Expected Orderbook/ Pending Orders?

Some backlog orders from the previous quarter due to shipping and supply chain issues (notably Red Sea disruptions) were cleared and reflected in the current quarter's revenue. However, some backlog still remains and has been incorporated into ongoing planning. The current quarter itself has created new backlog, which will carry over into the next quarter. Improved planning has helped address shipment delays to a large extent, stabilizing order fulfillment. Overall, the backlog situation is being actively managed but is not completely resolved yet, awaiting improvement in global shipping condi

Any current/future new fundraising through debt or equity?

Glenmark Life Sciences does not plan to raise debt for expansion; all expansion will be funded through internal accruals. The company aims to remain debt-free, with no requirement for leveraging the balance sheet at this stage. There was no mention of any immediate or future equity fundraising in the transcript. Current capex plans for FY '25 are between INR 300-350 crores, funded internally. The company may retain some cash on the balance sheet due to high capex commitment, leading to moderate dividend payout, but not specifying any fundraising through equity.

Any current/future capex/capital investment/strategic investment?

Current year (FY'25) capex planned between INR 300 crores to INR 340 crores. Major investment toward building greenfield site at Solapur, expected completion in about 18-20 months; total Solapur capex around INR 350-400 crores. Addition of new pharma capacity at Ankleshwar and Dahej plants (e.g., pharma modules in Q2 and Q4 FY'25). Investing in new R&D center to support expansion into new technology platforms and portfolio avenues with backing from Nirma. Capex to meet environmental regulations continues, including commissioning of third Effluent Treatment Plant (ETP) next month; any additiona

Future growth expectations in sales/revenue/volumes?

FY '25 started positively with close to 10% sequential revenue growth, indicating a strong and resilient business. Broad-based growth witnessed across geographies including India, Japan, and Rest of the World. Medium-term growth outlook remains unchanged with expectations of mid- to high-teens growth for the external business. Brownfield expansions have provided a runway of about 1.5 years to cater to additional demand. New greenfield Solapur facility under construction, expected to be completed in 18 to 20 months, will further boost capacity. CDMO segment expected to pick up from Q3 FY '25, w

Future growth expectations in earnings/operating earnings/profits/EPS?

Glenmark Life Sciences started FY '25 on a positive note with close to 10% sequential growth, indicating a strong and resilient business. The demand outlook is good, with growth expected to continue across regions over the next couple of quarters. The medium-term growth outlook remains unchanged with additional capacity coming online (e.g., Solapur Phase I to complete in 18-20 months). EBITDA margins are stable at around 28%, with expectations to maintain or improve margins from current levels. Gross margins have faced pressure due to product mix and the discontinuation of PLI benefits

IN US

Sale is live|00:00:00left today

Alivus Life Sciences LtdQ2 FY24Pharmaceuticals & Biotechnology

Alivus Life Sciences Ltd Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,108P/E: 22.7Market Cap: ₹12.7K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Order

Yes

Capex

Yes

2 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→FY '25 started positively with close to 10% sequential revenue growth, indicating a strong and resilient business.
→Broad-based growth witnessed across geographies including India, Japan, and Rest of the World.
→Medium-term growth outlook remains unchanged with expectations of mid- to high-teens growth for the external business.
→Brownfield expansions have provided a runway of about 1.5 years to cater to additional demand.
→New greenfield Solapur facility under construction, expected to be completed in 18 to 20 months, will further boost capacity.
→CDMO segment expected to pick up from Q3 FY '25, with additional projects in the pipeline and steady momentum.
→Pipeline continuously being filled, with 5 new products added recently; 20 high-potency APIs targeting a $4 billion market.
→Demand outlook is improving with increasing momentum in specialty and innovator segments.

Margin guidance

Category 3

→Glenmark Life Sciences started FY '25 on a positive note with close to 10% sequential growth, indicating a strong and resilient business.
→The demand outlook is good, with growth expected to continue across regions over the next couple of quarters.
→The medium-term growth outlook remains unchanged with additional capacity coming online (e.g., Solapur Phase I to complete in 18-20 months).
→EBITDA margins are stable at around 28%, with expectations to maintain or improve margins from current levels.
→Gross margins have faced pressure due to product mix and the discontinuation of PLI benefits but are not expected to decline further.
→Free cash flow generation is strong, supporting capex and potentially steady dividend payout, although dividend growth payout may moderate.
→Continued investment in capacity expansion (INR300-350 crores capex in FY '25) supports future revenue growth.
→Overall, stable margins with mid-to-high teens growth in external business revenues are anticipated.

3 more insights locked — sign up free to unlock

Fundraise plans

→Glenmark Life Sciences does not plan to raise debt for expansion; all expansion will be funded through internal accruals.
→The company aims to remain debt-free, with no requirement for leveraging the balance sheet at this stage.
→There was no mention of any immediate or future equity fundraising in the transcript.
→Current capex plans for FY '25 are between INR 300-350 crores, funded internally.
→The company may retain some cash on the balance sheet due to high capex commitment, leading to moderate dividend payout, but not specifying any fundraising through equity.

Order book

Yes

→Some backlog orders from the previous quarter due to shipping and supply chain issues (notably Red Sea disruptions) were cleared and reflected in the current quarter's revenue.
→However, some backlog still remains and has been incorporated into ongoing planning.
→The current quarter itself has created new backlog, which will carry over into the next quarter.
→Improved planning has helped address shipment delays to a large extent, stabilizing order fulfillment.
→Overall, the backlog situation is being actively managed but is not completely resolved yet, awaiting improvement in global shipping conditions.

Capex plans

Yes

→Current year (FY'25) capex planned between INR 300 crores to INR 340 crores.
→Major investment toward building greenfield site at Solapur, expected completion in about 18-20 months; total Solapur capex around INR 350-400 crores.
→Addition of new pharma capacity at Ankleshwar and Dahej plants (e.g., pharma modules in Q2 and Q4 FY'25).
→Investing in new R&D center to support expansion into new technology platforms and portfolio avenues with backing from Nirma.
→Capex to meet environmental regulations continues, including commissioning of third Effluent Treatment Plant (ETP) next month; any additional environmental capex expected to be marginal.
→Capex investment will be calibrated to align with demand, product mix, and regulatory approvals without overinvestment.
→Expansion funded through internal accruals; no new debt planned.
→Strategic focus on building specialty and CDMO business segments.

How does Alivus Life Sciences Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Alivus Life Sciences Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Alivus Life Sciences Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio